August 10, 2020 9:01 AM

As of June 29, MSU's Small Animal Emergency and Critical Care Medicine (ECCM) operations have modified:

All walk-in patients will be evaluated. Life-threatening cases will be admitted. Cases evaluated as stable will be referred to the client’s primary care veterinarian, other facilities, or other services within the MSU Hospital, if possible. Monday–Friday, from 8:00 a.m.–1:00 p.m., the ECCM Service will operate as a “referral only” service. However, walk-in patients with critical illness or immediately life-threatening problems will always receive care. Referring veterinarians should call 517-353-5420 prior to sending any patients to MSU. View the Hospital's full web page.

The Abramovitch Laboratory focuses on tuberculosis research and drug discovery at Michigan State University.

Mycobacterium tuberculosis causes tuberculosis in humans and is one of the leading causes of death by an infectious disease. A signature feature of M. tuberculosis pathogenesis is that the bacterium survives inside macrophages, a host immune cell that kills many other bacteria. The goals of Dr. Abramovitch's research program are to: 1) characterize how M. tuberculosis adapts to life inside a macrophage, and 2) apply these discoveries toward the development of new drugs. To achieve these goals, his team is using genetic, genomic, and biochemical approaches to characterize new genes and proteins that enable M. tuberculosis to succeed as an intracellular pathogen. These findings are then translated into high throughput screening platforms to identify small molecule compounds that interfere with M. tuberculosis adaptation physiology. In summary, the laboratory's mission is to make basic research discoveries that jump-start the development of new drugs to treat tuberculosis.

Robert Abramovitch, PhD, studies the mechanisms of Mycobacterium tuberculosis environmental adaptation.